Tearsheet

Humana (HUM)


Market Price (12/26/2025): $258.67 | Market Cap: $31.1 Bil
Sector: Health Care | Industry: Managed Health Care

Humana (HUM)


Market Price (12/26/2025): $258.67
Market Cap: $31.1 Bil
Sector: Health Care
Industry: Managed Health Care

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.


0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.5%
Weak multi-year price returns
2Y Excs Rtn is -89%, 3Y Excs Rtn is -129%
Key risks
HUM key risks include [1] a significant and financially impactful decline in its Medicare Advantage Star Ratings, Show more.
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -31%
  
2 Attractive cash flow generation
CFO LTM is 2.0 Bil
  
3 Low stock price volatility
Vol 12M is 44%
  
4 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Telehealth Platforms, Show more.
  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.5%
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -31%
2 Attractive cash flow generation
CFO LTM is 2.0 Bil
3 Low stock price volatility
Vol 12M is 44%
4 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Telehealth Platforms, Show more.
5 Weak multi-year price returns
2Y Excs Rtn is -89%, 3Y Excs Rtn is -129%
6 Key risks
HUM key risks include [1] a significant and financially impactful decline in its Medicare Advantage Star Ratings, Show more.

Valuation, Metrics & Events

HUM Stock


Why The Stock Moved


Qualitative Assessment

AI Analysis | Feedback

Here are the key points for why Humana's (HUM) stock moved by -14.3% during the approximate time period from August 31, 2025, to December 26, 2025: 1. Disappointing Q3 2025 Earnings Outlook: Humana's Q3 2025 earnings report, released in early November 2025, caused a significant stock drop despite an adjusted earnings per share (EPS) beat. Investors reacted negatively to a downward revision of the full-year GAAP EPS guidance and heightened concerns over rising medical costs, specifically a projected higher insurance benefit ratio of 93.5% for Q4, signaling potential margin pressure.

2. Loss of Medicare Advantage Star Ratings Challenge: In October 2025, a U.S. judge rejected Humana's lawsuit challenging the Centers for Medicare & Medicaid Services' (CMS) 2025 star ratings for its Medicare Advantage plans. This legal defeat upheld a significant downgrade in star ratings for a key contract, which was expected to reduce billions in bonus payments and negatively impact the company's 2026 revenues.

3. Show more

Stock Movement Drivers

Fundamental Drivers

The 1.9% change in HUM stock from 9/25/2025 to 12/25/2025 was primarily driven by a 24.1% change in the company's P/E Multiple.
925202512252025Change
Stock Price ($)254.43259.251.89%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)123110.00126362.002.64%
Net Income Margin (%)1.28%1.02%-20.19%
P/E Multiple19.4624.1524.11%
Shares Outstanding (Mil)120.54120.270.22%
Cumulative Contribution1.89%

LTM = Last Twelve Months as of date shown

Market Drivers

9/25/2025 to 12/25/2025
ReturnCorrelation
HUM1.9% 
Market (SPY)4.9%21.4%
Sector (XLV)16.2%25.8%

Fundamental Drivers

The 8.8% change in HUM stock from 6/26/2025 to 12/25/2025 was primarily driven by a 43.7% change in the company's P/E Multiple.
626202512252025Change
Stock Price ($)238.18259.258.84%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)120262.00126362.005.07%
Net Income Margin (%)1.42%1.02%-28.15%
P/E Multiple16.8124.1543.70%
Shares Outstanding (Mil)120.67120.270.33%
Cumulative Contribution8.84%

LTM = Last Twelve Months as of date shown

Market Drivers

6/26/2025 to 12/25/2025
ReturnCorrelation
HUM8.8% 
Market (SPY)13.1%15.8%
Sector (XLV)16.6%30.0%

Fundamental Drivers

The 2.9% change in HUM stock from 12/25/2024 to 12/25/2025 was primarily driven by a 9.9% change in the company's Total Revenues ($ Mil).
1225202412252025Change
Stock Price ($)251.98259.252.88%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)115010.00126362.009.87%
Net Income Margin (%)1.18%1.02%-13.54%
P/E Multiple22.3324.158.19%
Shares Outstanding (Mil)120.41120.270.11%
Cumulative Contribution2.88%

LTM = Last Twelve Months as of date shown

Market Drivers

12/25/2024 to 12/25/2025
ReturnCorrelation
HUM2.9% 
Market (SPY)15.8%16.1%
Sector (XLV)13.3%35.8%

Fundamental Drivers

The -48.0% change in HUM stock from 12/26/2022 to 12/25/2025 was primarily driven by a -66.7% change in the company's Net Income Margin (%).
1226202212252025Change
Stock Price ($)498.37259.25-47.98%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)91485.00126362.0038.12%
Net Income Margin (%)3.07%1.02%-66.70%
P/E Multiple22.4724.157.48%
Shares Outstanding (Mil)126.57120.274.98%
Cumulative Contribution-48.11%

LTM = Last Twelve Months as of date shown

Market Drivers

12/26/2023 to 12/25/2025
ReturnCorrelation
HUM-41.4% 
Market (SPY)48.3%13.7%
Sector (XLV)18.5%35.4%

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
HUM Return13%14%11%-10%-44%2%-26%
Peers Return4%39%11%-7%-18%2%26%
S&P 500 Return16%27%-19%24%23%18%115%

Monthly Win Rates [3]
HUM Win Rate50%42%67%42%25%50% 
Peers Win Rate47%55%55%42%50%57% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
HUM Max Drawdown-41%-9%-22%-17%-49%-13% 
Peers Max Drawdown-34%-6%-9%-23%-23%-29% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: UNH, ELV, CVS, CI, CNC. See HUM Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)

How Low Can It Go

Unique KeyEventHUMS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-24.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven32.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-43.6%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven77.3%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven38 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-34.2%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven52.0%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven243 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-78.4%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven363.4%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven977 days1,480 days

Compare to UNH, CI, CNC, MOH, ELV

In The Past

Humana's stock fell -24.6% during the 2022 Inflation Shock from a high on 11/3/2022. A -24.6% loss requires a 32.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Humana (HUM)

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

AI Analysis | Feedback

Here are 1-3 brief analogies for Humana (HUM):

  • Humana is like UnitedHealth Group (UnitedHealthcare), providing health insurance plans, especially for seniors through Medicare.
  • Humana is like CVS Health's Aetna, a major health insurer, but with a particular emphasis on Medicare plans.
  • Humana is like the Allstate or Progressive for health insurance, specializing in covering medical costs for individuals and employers, particularly seniors.

AI Analysis | Feedback

Humana provides a range of health and well-being services, primarily focusing on health insurance plans.
  • Medicare Advantage Plans: These are private health insurance plans that contract with Medicare to provide beneficiaries with all their Part A and Part B benefits, often including prescription drug coverage and additional benefits.
  • Medicare Supplement Plans (Medigap): These plans help pay for out-of-pocket costs that Original Medicare doesn't cover, such as deductibles, copayments, and coinsurance.
  • Prescription Drug Plans (Part D): Stand-alone plans that provide coverage for prescription medications to individuals enrolled in Original Medicare.
  • Commercial Group Health Plans: Health insurance plans offered by employers to their employees, providing medical, pharmacy, and sometimes specialty benefits.
  • Medicaid Managed Care Plans: Health plans offered to eligible low-income individuals and families, administered through state contracts.
  • Specialty Benefits: Supplemental insurance products such as dental, vision, life, and short-term disability insurance.
  • Healthcare Services: Provides various healthcare services including home health, pharmacy services, and clinic operations, often integrating with their insurance plans.

AI Analysis | Feedback

```html

For the public company Humana (symbol: HUM), it primarily sells its health insurance products and services to individuals, often categorized by the type of health plan they select or are eligible for. While Humana does serve employer groups, the ultimate beneficiaries and thus the "customers" in terms of healthcare services are the individuals enrolled in their plans.

The up to three major categories of customers Humana serves are:

  • Medicare Members: This is a significant portion of Humana's business. These customers are individuals aged 65 and older, or younger individuals with certain disabilities, who enroll in Humana's Medicare Advantage plans (Part C), standalone Prescription Drug Plans (Part D), or Medicare Supplement plans.
  • Medicaid Members: Humana serves individuals with low incomes who qualify for government assistance through its Medicaid managed care plans. Humana partners with various state governments to administer these programs.
  • Commercial Members: This category includes individuals who receive their health insurance through their employer (group plans) or those who purchase health plans directly from Humana on the individual market (often through the Affordable Care Act exchanges).
```

AI Analysis | Feedback

  • CVS Health (CVS)

AI Analysis | Feedback

James Rechtin, President and Chief Executive Officer

James Rechtin became Humana's President and Chief Executive Officer in July 2024, after joining the company as President and Chief Operating Officer in January 2024. Before his tenure at Humana, he held the position of President and CEO at Envision Healthcare. He also served as President of OptumCare, a part of UnitedHealth Group, and held senior leadership roles at DaVita Medical Group, including Senior Vice President of Corporate Strategy and President of its California market. While he was at DaVita Medical Group, the company was acquired by OptumCare. Rechtin spent 14 years in the healthcare sector with Bain & Company and began his career running operations for a nonprofit clinic and serving in the Peace Corps. His experience at Envision Healthcare, which has been backed by private equity, indicates involvement with privately funded entities.

Celeste Mellet, Chief Financial Officer

Celeste Mellet is slated to become Humana's Chief Financial Officer effective January 11, 2025, succeeding Susan Diamond. She currently serves as the CFO of Global Infrastructure Partners (GIP), an infrastructure fund manager that was recently acquired by BlackRock. Prior to GIP, she was the CFO, Senior Managing Director, and Executive Vice President at Evercore. Mellet also held the position of Executive Vice President and CFO at Fannie Mae and spent over 18 years at Morgan Stanley, where her roles included global treasurer and head of investor, creditor, and counterparty relations.

Susan Diamond, Advisor (Former Chief Financial Officer)

Susan Diamond served as Humana's Chief Financial Officer from 2021 until January 2025 and will remain in an advisory role through the end of 2025. She joined Humana in 2006 and held various financial and operational leadership roles within the Medicare and Home businesses, including President of Home Solutions and Senior Vice President of Medicare. Before joining Humana, Diamond was CFO for Smoothstone IP Communications and Prosperitas Investment Partners. She also gained six years of experience in financial leadership roles for early-stage, venture-backed technology companies and spent five years as CFO for a Louisville-based venture capital firm. Diamond led Humana's acquisition of the remaining 60 percent interest in Kindred at Home, a $5.7 billion deal that was the largest in Humana's history.

David Dintenfass, President, Enterprise Growth

David Dintenfass joined Humana in February 2024 as President, Enterprise Growth. In this role, he is responsible for leading the company's growth strategy, with a focus on customer acquisition, retention, and experience. Dintenfass brings over 30 years of experience from various sectors, including consumer banking, wealth and asset management, and consumer-packaged goods.

Dr. Sanjay K. Shetty, President, CenterWell

Dr. Sanjay K. Shetty joined Humana in March 2023 as President of CenterWell. He is responsible for leading the strategy, growth, and business operations of Humana's healthcare services businesses, which include Pharmacy, Provider Services, and Home Solutions. Additionally, Dr. Shetty oversees the Humana Military segment.

AI Analysis | Feedback

The public company Humana (HUM) faces several key risks to its business, primarily concentrated within its significant Medicare Advantage segment.

  1. Medicare Advantage Star Ratings Decline: Humana experienced a significant drop in its Medicare Advantage (MA) Star Ratings for 2025, with only approximately 25% of its MA members now enrolled in plans rated 4-star or higher, a sharp decline from 94% in 2024. This downgrade has substantial financial implications, as higher-rated plans receive increased reimbursement rates and are more attractive to prospective enrollees. The company anticipates that these lower ratings will negatively impact its 2026 earnings, and it has initiated a lawsuit challenging the Centers for Medicare & Medicaid Services' (CMS) 2025 Star Ratings.
  2. Rising Medical Cost Trends: Humana is significantly challenged by continued medical cost inflation and unpredictable healthcare utilization trends, particularly within its Medicare Advantage business. Increased use of medical facilities and services, higher prescription drug costs (especially for specialty drugs), and the introduction of new or costly treatments contribute to these elevated costs, which can significantly pressure the company's profitability and margins.
  3. Regulatory and Governmental Policy Changes: As a company with a substantial portion of its revenue derived from government contracts, Humana is highly susceptible to various regulatory risks and changes in government healthcare policies. These risks extend beyond Star Ratings and include potential reductions in Medicare reimbursement rates, alterations to CMS's risk adjustment models, and other legislative or regulatory changes impacting the Medicare Advantage and Prescription Drug Plan programs. Such changes can materially affect Humana's operations, financial position, and cash flows.

AI Analysis | Feedback

One clear emerging threat for Humana stems from the aggressive expansion of major retailers and tech giants into integrated healthcare services. Companies like Amazon and Walmart are actively building comprehensive ecosystems that could fundamentally alter how consumers access and pay for healthcare, directly challenging traditional health insurers like Humana.

  • Amazon's continued investments in healthcare, including its acquisition of One Medical (primary care clinics) and its robust Amazon Pharmacy operations, indicate a strategic intent to simplify and integrate healthcare delivery. While Amazon Care was discontinued, the underlying strategy of offering accessible, tech-driven healthcare solutions remains. If Amazon were to bundle these services into a compelling subscription model or a streamlined Medicare offering that emphasizes convenience and integrated care directly to consumers, it could significantly disrupt Humana's Medicare Advantage business by providing an alternative, tech-forward pathway to care that bypasses traditional insurance complexities.
  • Walmart's rapid expansion of its "Walmart Health" centers, which offer primary care, dental, optometry, and behavioral health services at transparent, often lower prices, poses another significant emerging threat. Walmart's strategy is to become a comprehensive, affordable healthcare provider for communities. Should Walmart continue to expand this footprint and potentially integrate these services with its own branded health plans or highly preferred partner plans, it could capture a significant portion of the cost-conscious Medicare Advantage population, undermining Humana's established provider networks and care coordination models.

These developments are not speculative; they are observable trends of powerful, customer-centric companies actively building infrastructure and services that could offer alternatives to traditional health insurance, similar to how Netflix disrupted Blockbuster by offering a new, more convenient delivery model.

AI Analysis | Feedback

Humana Inc. (NYSE: HUM) is a prominent health insurance company in the U.S., primarily offering Medicare Advantage plans, prescription drug plans, Medicaid services, and healthcare services through its CenterWell segment, which includes home-based care and pharmacy benefit management. The addressable markets for Humana's main products and services in the United States are as follows:

  • Medicare Advantage: The U.S. Medicare Advantage market accounted for approximately $462 billion of total federal Medicare spending in 2024.
  • Pharmacy Benefit Management (PBM): The U.S. pharmacy benefit management market was valued at $587.4 billion in 2024 and is projected to reach $638.0 billion in 2025.
  • Home Healthcare Services: The U.S. home healthcare market size was estimated at $194.24 billion in 2024 and is projected to reach approximately $222.61 billion by 2025.
  • Medicaid Managed Care: null
  • Specialty Benefits (Dental and Vision Insurance): null
  • Employer Group Health Plans: null

AI Analysis | Feedback

Humana (NYSE: HUM) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market dynamics:

  1. Growth in Medicare Advantage (MA) Membership and Optimized Product Offerings: Humana, a prominent player in the Medicare Advantage market, anticipates sustained multi-year member growth. The company is actively focusing on enhancing its Stars ratings, with an aim to achieve top-quartile performance by the 2027-2028 plan year. Improved Stars ratings are crucial as they directly influence quality bonus payments, a significant revenue component. Humana is also implementing incremental pricing adjustments in its MA plans to mitigate reimbursement pressures and is customizing benefits by segment to boost retention and attract new members.
  2. Expansion of CenterWell and Value-Based Care Models: The CenterWell segment, which encompasses Humana's primary care, pharmacy, and home health services, is a significant growth engine. This division has consistently demonstrated robust revenue growth, driven by its pharmacy services and increasing patient base in primary care. Humana is strategically expanding its value-based care models, including through the addition of new care centers, which is expected to lead to increases in both patients and memberships and support overall revenue growth.
  3. Growth in Medicaid and Other Government-Sponsored Programs: Beyond Medicare Advantage, Humana maintains a substantial presence in government-sponsored healthcare programs, including Medicaid and Tricare. The company has been actively expanding its Medicaid footprint, now covering 13 states, and is exploring new opportunities in dual-eligible Medicaid programs across various states. Membership growth in these state-based contracts and standalone prescription drug plan (PDP) businesses is expected to contribute to future revenue.
  4. Favorable Demographic Trends: Humana's core business benefits significantly from the broader demographic shift in the United States. The 65+ population is projected to grow by 13% between 2024 and 2030, alongside an anticipated 6 percentage point increase in Medicare Advantage penetration by 2030, which could add approximately 9 million new enrollees to the market. These underlying demographic trends provide a strong and sustained tailwind for Humana's target market and revenue expansion.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

  • Humana's Board of Directors approved a new $3 billion share repurchase authorization in February 2024, replacing a prior authorization.
  • The company repurchased $750 million in shares during the first six months of 2024.
  • Annual share repurchases amounted to $817 million in 2024, $1.573 billion in 2023, and $2.096 billion in 2022.

Share Issuance

  • Humana issued $1.5 billion in senior notes in March 2025, which contributed to an increase in its debt-to-total capitalization.

Outbound Investments

  • In August 2021, Humana acquired the remaining 60% interest in Kindred at Home for an enterprise value of $8.2 billion, with approximately $5.8 billion paid (net of existing equity stake) through a combination of debt financing, assumed indebtedness, and cash.
  • The company acquired home-based healthcare and care coordination services provider Onehome in June 2021 and managed care organization Inclusa in August 2022.
  • Humana is expanding its CenterWell platform, with expectations for 20% patient panel growth and 15% growth in centers by 2024, emphasizing integrated care services.

Capital Expenditures

  • Expected capital expenditures for fiscal year 2025 are approximately $650 million.
  • Expected capital expenditures for fiscal year 2024 were approximately $800 million.
  • The primary focus of capital expenditures includes investments in technology and data analytics, such as the Humana studio_h in Boston for digital health solutions.

Trade Ideas

Select ideas related to HUM. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
21.1%21.1%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-6.7%-6.7%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
16.7%16.7%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
11.8%11.8%-5.1%

Recent Active Movers

More From Trefis

Peer Comparisons for Humana

Peers to compare with:

Financials

HUMUNHELVCVSCICNCMedian
NameHumana UnitedHe.Elevance.CVS Heal.Cigna Centene  
Mkt Price259.25327.58343.3079.12274.8639.89267.06
Mkt Cap31.2296.876.7100.473.219.674.9
Rev LTM126,362435,159194,820394,084261,220185,857228,020
Op Inc LTM-26,357-10,751-1,09510,751
FCF LTM1,54717,3723,7676,2933,9443,3563,856
FCF 3Y Avg73218,9684,2956,4277,7733,0175,361
CFO LTM2,04520,9584,9129,1095,2924,0645,102
CFO 3Y Avg1,46422,4435,5199,2779,1973,7617,358

Growth & Margins

HUMUNHELVCVSCICNCMedian
NameHumana UnitedHe.Elevance.CVS Heal.Cigna Centene  
Rev Chg LTM9.9%10.5%12.0%6.8%20.9%14.9%11.2%
Rev Chg 3Y Avg11.4%11.4%8.4%7.7%13.6%9.6%10.5%
Rev Chg Q11.1%12.2%12.3%7.8%11.2%18.2%11.7%
QoQ Delta Rev Chg LTM2.6%2.9%2.9%1.9%2.7%4.3%2.8%
Op Mgn LTM-6.1%-2.7%-0.6%2.7%
Op Mgn 3Y Avg-7.7%-3.3%-1.7%3.3%
QoQ Delta Op Mgn LTM--1.2%-0.1%--0.5%-0.5%
CFO/Rev LTM1.6%4.8%2.5%2.3%2.0%2.2%2.2%
CFO/Rev 3Y Avg1.4%5.8%3.1%2.5%4.4%2.3%2.8%
FCF/Rev LTM1.2%4.0%1.9%1.6%1.5%1.8%1.7%
FCF/Rev 3Y Avg0.8%4.9%2.4%1.8%3.8%1.9%2.2%

Valuation

HUMUNHELVCVSCICNCMedian
NameHumana UnitedHe.Elevance.CVS Heal.Cigna Centene  
Mkt Cap31.2296.876.7100.473.219.674.9
P/S0.20.70.40.30.30.10.3
P/EBIT13.311.39.016.78.8-4.710.2
P/E24.216.913.9214.114.6-3.715.7
P/CFO15.214.215.611.013.84.814.0
Total Yield5.5%8.6%9.2%3.8%9.0%-27.0%7.0%
Dividend Yield1.4%2.6%2.0%3.4%2.2%0.0%2.1%
FCF Yield 3Y Avg0.6%4.5%4.7%7.1%9.0%11.5%5.9%
D/E0.40.30.40.80.40.90.4
Net D/E-0.30.2-0.00.70.4-0.10.1

Returns

HUMUNHELVCVSCICNCMedian
NameHumana UnitedHe.Elevance.CVS Heal.Cigna Centene  
1M Rtn9.0%1.1%2.6%0.8%-0.6%0.6%1.0%
3M Rtn1.9%-4.6%9.0%6.9%-2.7%16.0%4.4%
6M Rtn8.8%9.7%-7.0%18.3%-15.8%-25.5%0.9%
12M Rtn2.9%-33.7%-6.2%86.4%0.2%-34.4%-3.0%
3Y Rtn-48.0%-34.9%-30.2%-5.2%-13.2%-51.1%-32.5%
1M Excs Rtn9.7%-0.0%1.3%-1.8%-1.6%1.1%0.6%
3M Excs Rtn-3.1%-9.5%4.0%2.0%-7.7%11.0%-0.6%
6M Excs Rtn-4.0%-3.2%-19.9%5.5%-28.7%-38.4%-12.0%
12M Excs Rtn-10.5%-49.8%-21.3%69.1%-15.6%-49.9%-18.4%
3Y Excs Rtn-128.6%-115.5%-110.1%-88.2%-93.8%-132.6%-112.8%

Financials

Segment Financials

Revenue by Segment
$ Mil20242023202220212020
Insurance102,85488,84180,675  
CenterWell18,40517,3072,202 25,783
Eliminations/Corporate-14,885-13,278 -25,876-24,886
Investment income  187  
Group and Specialty   7,2857,525
Healthcare Services   28,448 
Retail   67,29856,466
Total106,37492,87083,06477,15564,888


Price Behavior

Price Behavior
Market Price$259.25 
Market Cap ($ Bil)31.2 
First Trading Date12/31/1981 
Distance from 52W High-16.6% 
   50 Days200 Days
DMA Price$259.34$257.70
DMA Trendindeterminatedown
Distance from DMA-0.0%0.6%
 3M1YR
Volatility46.8%44.1%
Downside Capture93.1326.80
Upside Capture80.9525.59
Correlation (SPY)22.1%16.1%
HUM Betas & Captures as of 11/30/2025

 1M2M3M6M1Y3Y
Beta0.580.770.700.610.350.33
Up Beta0.02-0.560.410.590.390.41
Down Beta1.332.401.881.670.470.36
Up Capture-66%19%-35%19%7%2%
Bmk +ve Days12253873141426
Stock +ve Days9223470133387
Down Capture134%68%79%14%42%71%
Bmk -ve Days7162452107323
Stock -ve Days10192855115362

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
 Comparison of HUM With Other Asset Classes (Last 1Y)
 HUMSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return11.5%16.4%19.2%71.9%8.9%6.0%-10.1%
Annualized Volatility44.1%17.3%19.5%19.3%15.3%17.1%35.0%
Sharpe Ratio0.370.720.782.690.360.18-0.12
Correlation With Other Assets 36.5%16.7%-8.8%1.9%15.9%4.5%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
 Comparison of HUM With Other Asset Classes (Last 5Y)
 HUMSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-7.2%8.6%14.9%18.7%11.7%4.8%32.7%
Annualized Volatility34.3%14.5%17.1%15.5%18.7%18.9%48.7%
Sharpe Ratio-0.140.410.700.970.510.170.60
Correlation With Other Assets 40.7%20.6%-3.6%-1.2%16.5%10.2%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
 Comparison of HUM With Other Asset Classes (Last 10Y)
 HUMSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return4.8%9.8%14.7%14.9%6.9%5.2%69.3%
Annualized Volatility33.0%16.6%18.0%14.8%17.6%20.8%55.8%
Sharpe Ratio0.230.480.700.830.310.220.90
Correlation With Other Assets 53.5%39.8%-2.9%11.4%32.4%10.2%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date12152025
Short Interest: Shares Quantity4,819,305
Short Interest: % Change Since 113020250.7%
Average Daily Volume1,630,675
Days-to-Cover Short Interest2.96
Basic Shares Quantity120,273,000
Short % of Basic Shares4.0%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/2025-6.0%-13.6%-8.5%
7/30/202512.4%9.4%27.8%
4/30/20251.1%-2.9%-11.3%
10/30/20243.3%1.1%15.1%
7/31/2024-10.6%-12.2%-12.9%
4/24/2024-3.7%-7.9%8.7%
1/25/2024-11.7%-6.0%-9.8%
11/1/2023-6.6%-4.9%-7.4%
...
SUMMARY STATS   
# Positive151312
# Negative81011
Median Positive3.0%4.2%8.4%
Median Negative-5.9%-6.0%-7.8%
Max Positive12.4%10.8%27.8%
Max Negative-11.7%-13.6%-13.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
93020251105202510-Q 9/30/2025
6302025730202510-Q 6/30/2025
3312025430202510-Q 3/31/2025
12312024220202510-K 12/31/2024
93020241030202410-Q 9/30/2024
6302024731202410-Q 6/30/2024
3312024424202410-Q 3/31/2024
12312023215202410-K 12/31/2023
93020231101202310-Q 9/30/2023
6302023802202310-Q 6/30/2023
3312023426202310-Q 3/31/2023
12312022216202310-K 12/31/2022
93020221102202210-Q 9/30/2022
6302022727202210-Q 6/30/2022
3312022427202210-Q 3/31/2022
12312021217202210-K 12/31/2021